**What's Known**

Several studies have examined the prevalence of CTX-Ms in ESBLs-producing *K. pneumoniae* clinical isolates in different geographical regions of Iran.The average rate of CTX-M enzymes among ESBLs-producing *K. pneumoniae* isolates has not been clearly identified in Iran.

**What's New**

We reviewed published studies regarding the prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates in Iran and presented an overall relative frequency (RF).The overall RF of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates in Iran is 56.7%.

Introduction {#sec1-1}
============

Extended-spectrum β-lactamases (ESBLs) are bacterial enzymes that confer resistance to penicillins, broad-spectrum oxyimino-cephalosporins and aztreonam, but suppressed by serine-type β-lactamase inhibitors (e.g. clavulanic acid). ESBLs can be encoded through both chromosome and plasmid genes, and more than ten families have been so far documented to be associated with ESBLs, including CTX-M, SHV, TEM, PER, VEB, BES, GES, TLA, SFO, and OXA.^[@ref1]-[@ref3]^ CTX-M-type ESBLs are plasmid-encoded enzymes that have been detected in at least 26 bacterial species. CTX-Ms are the most prevalent ESBLs in Enterobacteriaceae particularly in *Escherichia coli*, *Klebsiella pneumoniae*, and *Proteus mirabilis*. ^[@ref1],[@ref3]-[@ref5]^ A member of the Enterobacteriaceae family, *K. pneumoniae* strains are ubiquitous in nature and exist specifically in natural environments and on mucosal surfaces of mammals. This microorganism is an opportunistic bacterial pathogen that commonly causes different infections in human. ^[@ref6]-[@ref8]^ . pneumoniae is one of the major ESBLs-producing bacteria. ESBLs-producing *K. pneumoniae* is more prevalent in Asia and South America, ^[@ref9]^ and has recently been listed as one of the six drug-resistant pathogens for which few potentially effective drugs are available.^[@ref10]^ The worldwide spread of CTX-M-producing *K. pneumoniae* is a major concern in most continents such as Asia.^[@ref11]-[@ref13]^ Recently, high rate of CTX-M enzymes (as high as 58.5%) among ESBLs-producing *K. pneumoniae* isolates have been reported in many countries including Brazil, ^[@ref12]^ Spain,^[@ref14]^ Korea,^[@ref15]^ etc.

To date, several studies have examined the prevalence of CTX-Ms in ESBLs-producing *K. pneumoniae* clinical isolates in different geographical regions of Iran. Nevertheless, the average rate of CTX-M enzymes among ESBLs-producing *K. pneumoniae* isolates has not been clearly identified in Iran. Therefore, in this meta-analysis, we reviewed published studies regarding the prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates in Iran and presented an overall relative frequency (RF).

Materials and Methods {#sec1-2}
=====================

*Search Strategy* {#sec2-1}
-----------------

To identify all related published studies, we searched PubMed, Scopus, EBSCO, Embase, Google Scholar, Scirus and four Persian scientific search engines including IranMedex, IRANDOC, Magiran, and scientific information database (SID) in both English and Persian. The medical subject headings (MESH) and keywords used for the search were "Enterobacteriaceae" and "*Klebsiella pneumoniae* or *K. pneumoniae*" and "Extended-spectrum β-lactamases or ESBLs" and "CTX-M" and "Iran". The searched keywords were adapted to the primary language of the database. We also searched the references cited in these articles to find other relevant articles. Selected articles were published between July 2010 and July 2016 and all of them were in English.

*Inclusion Criteria* {#sec2-2}
--------------------

Among obtained articles/abstracts, those with the following features were included in the study:

1.  a- Articles that have assessed the prevalence of*bla~CTX-M~* gene

2.  b- Clinical isolates that were collected from Iranian hospitals

3.  c- Clinical isolates that were taken from patients (both inpatients and outpatients)

4.  d- Samples that only belonged to the genus*Klebsiella*, species *pneumoniae*

5.  e- Phenotypic confirmatory ESBL test (either combination disk test or double disc synergy test) which were used to detect ESBL production

6.  f- Only ESBLs-producing isolates which were confirmed by phenotypic ESBL test.

*Exclusion Criteria* {#sec2-3}
--------------------

Studies with at least one of the following criteria were excluded from our study:

1.  a- Samples that were totally/partially selected from ESBLs collections

2.  b- The origin of samples (region or population) was not clear

3.  c- Unclear report of the results

*Statistical Analysis* {#sec2-4}
----------------------

Statistical analysis was executed by the STATA software, version 11.0 (StataCorp, College Station, TX, USA). The overall RF of CTX-M in Iran was pooled by forest plot using the Meta-Analyst software. Heterogeneity among studies was assessed by Cochrane's Q-test and I^2^ measurement, which was interpreted as the proportion of total variation contributed among study variants. A P≤0.10 and an I^2^ value ≥50% shown significant heterogeneity. A random-effect model was applied in the incidence of significant heterogeneity; if not, a fixed-effect model was executed.

Results {#sec1-3}
=======

According to heterogeneity test, random model methods were performed for meta-analysis tests (P\<0.001). The I^2^\>50% indicated the presence of heterogeneity in our pooled analysis.

Out of all papers found by the search of databases, 24 articles matched our inclusion criteria (20 full-text articles and 4 abstracts) selected for our pooled analysis ^[@ref16]-[@ref35]^ ([table 1](#T1){ref-type="table"}). ). A detailed flowchart showing the selection process is presented in [figure 1](#IJMS-43-347-g001.tif){ref-type="fig"}. These studies were conducted in 10 provinces and 11 cities of Iran. The prevalence of ESBLs among *K. pneumoniae* clinical isolates varied from 28% in Kerman^[@ref21]^ to 74% in Tehran,^[@ref19]^ with the mean of 49%. The prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates varied from 7.7% in Tabriz19 to 100% in Mashhad, Tehran and Zahedan,^[@ref23],[@ref33],[@ref35]^ with the mean of 56.7%. In Tehran, the capital city of Iran, the prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates varied from 20.6% to 100%, with the mean of 61.7%.^[@ref18],[@ref19],[@ref27]-[@ref33]^ Pooled estimation of *K. pneumoniae* samples revealed that 55.9% (95% CI=43.0-68.9) of strains are CTX-M positive. [Figure 2](#IJMS-43-347-g002.tif){ref-type="fig"} demonstrates the forest plot of the relative frequency of*bla~CTX-M~* gene among different studies performed in Iran.

###### 

Characteristics of studies included in meta-analysis

  City      Hospitals name                                Sample size   Number of isolates carrying the*bla~CTX-M~* gene   Relative frequency of*bla~CTX-M~* gene (%)   Study team (reference no.)           Year published
  --------- --------------------------------------------- ------------- -------------------------------------------------- -------------------------------------------- ------------------------------------ -----------------
  Ahvaz     Golestan, Razi                                26            7                                                  26.9                                         Khosravi et al.^[@ref16]^            2013
  Arak      Educational hospitals of Medical University   41            36                                                 87.8                                         Safari et al.^[@ref17]^              2013
  Ilam      Emam Khomaini, Mostafa Khomaini, Ghaem        43            10                                                 23.3                                         Ghafourian et al.^[@ref18]^          2012
  Ilam      Emam Khomaini, Mostafa Khomaini, Ghaem        17            5                                                  29.4                                         Ghafourian et al.^[@ref19]^          2011
  Kashan    Hospitals in Kashan                           35            28                                                 80                                           Firoozeh et al.^[@ref20]^            2014
  Kerman    Afzali Poor, Kashani, Bahonar                 33            16                                                 48.5                                         Mansouri et al.^[@ref21]^            2014
  Kerman    Hospitals in Kerman                           31            6                                                  20                                           Mansouri et al.^[@ref22]^            2012 (abstract)
  Mashhad   Qaem, 17-Shahrivar                            9             9                                                  100                                          Moghaddam et al.^[@ref23]^           2014
  Shiraz    Namazi                                        36            25                                                 69.4                                         Ghasemi et al.^[@ref24]^             2013
  Tabriz    Emam Reza                                     45            7                                                  15.5                                         Ghafourian et al.^[@ref25]^          2011
  Tabriz    Sina                                          45            26                                                 57.8                                         Pormohammad et al.^[@ref26]^         2014 (abstract)
  Tabriz    Emam Reza                                     21            4                                                  19                                           Ghafourian et al.^[@ref18]^          2012
  Tabriz    Emam Reza                                     13            1                                                  7.7                                          Ghafourian et al.^[@ref19]^          2011
  Tehran    10 hospitals                                  102           73                                                 71.6                                         Nematzadeh et al.^[@ref27]^          2011
  Tehran    3 general and 2 private hospitals             77            45                                                 58.4                                         Nasehi et al.^[@ref28]^              2010
  Tehran    Hospitals in Tehran                           72            45                                                 62.5                                         Peerayeh et al.^[@ref29]^            2014 (abstract)
  Tehran    Milad                                         68            14                                                 20.6                                         Ghafourian et al.^[@ref18]^          2012
  Tehran    Taleghani, Mofid                              48            30                                                 62.5                                         Hashemi et al.^[@ref30]^             2014
  Tehran    Taleghani, Mofid                              48            28                                                 58.3                                         Taherpour et al.^[@ref31]^           2013
  Tehran    Mofid                                         19            18                                                 94.7                                         Karimi et al.^[@ref32]^              2012
  Tehran    Milad                                         37            10                                                 27                                           Ghafourian et al.^[@ref19]^          2011
  Tehran    Loghman-E Hakim, Imam Khomeini, Milad         17            17                                                 100                                          Derakhshan et al.^[@ref33]^          2014
  Zabol     Amir Al-Momenin                               20            13                                                 65                                           Saeidi et al.^[@ref34]^              2014
  Zahedan   Ali ibn Abi Talib, Khatamal Anbiya, Buali     51            51                                                 100                                          Shahraki-Zahedani et al.^[@ref35]^   2016

![Flowchart of the study selection process.](IJMS-43-347-g001){#IJMS-43-347-g001.tif}

![Forest plot of the current relative frequency of*bla~CTX-M~* gene among ESBLs-producing *Klebsiella pneumoniae* clinical isolates in different Iranian studies.](IJMS-43-347-g002){#IJMS-43-347-g002.tif}

Discussion {#sec1-4}
==========

In recent years, numerous studies by Iranian researchers have been conducted to identify*bla~CTX-M~* gene variants among ESBLs-producing *K. pneumoniae* clinical isolates. Based on these studies, this review presented a meta-analysis to show the prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates in Iran. Based on our results, the CTX-M-type ESBLs-producing *K. pneumoniae* is less frequent in western cities compared to central and eastern cities. The mean prevalence of ESBLs among *K. pneumoniae* clinical isolates in Iran was 49% that, on average, 56.7% of these isolates (ESBLs-producing isolates) possessed*bla~CTX-M~* gene. Lee et al.,^[@ref11]^ in their study on *K. pneumoniae* clinical isolates in 9 Asian countries have shown that ESBLs-production rates differed amongst the studied countries. The percentage of ESBLs-producers was low in Hong Kong and Taiwan (7.7% and 8.3%, respectively), but was high in South Korea, India, and Thailand (66.7%, 57.1%, and 55.3%, respectively). Moreover, they showed that 72.8% of ESBLs-producing isolates were possessed*bla~CTX-M~* gene which amongst, *bla~CTX-M-15~* was the major variant. Similarly, in Iran, the sequencing results in some studies demonstrated that the major variants of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates are*bla~CTX-M-15~* ^[@ref23],[@ref26],[@ref29],[@ref30],[@ref32],[@ref35]-[@ref37]^ followed by*bla~CTX-M-8~*,^[@ref35],[@ref36]^*bla~CTX-M-3~* and*bla~CTX-M-22~*.^[@ref26]^ From a regional stand, Iran has a higher mean prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates compared to reports from neighboring countries including Turkey (30%),^[@ref38],[@ref39]^ Saudi Arabia (35.3%), ^[@ref40],[@ref41]^ Iraq (45.2%), ^[@ref42],[@ref43]^ and Bahrain (10%)^[@ref44]^ as well as lower mean prevalence compared to Pakistan (96.9%),^[@ref45],[@ref46]^ Kuwait (100%),^[@ref47]^ and United Arab Emirates (64.4%). ^[@ref48]^ In a continental perspective, Iran has a lower mean prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates compared to reports from East Asian countries (78.8%).^[@ref11],[@ref49]^ At the international level, mean prevalence of*bla~CTX-M~* gene among ESBLs-producing *K. pneumoniae* clinical isolates in Iran is higher than USA (26.4%),^[@ref50]^ Russia (34.9%),^[@ref51]^ and South Africa (7.4%) ^[@ref39]^ as well as lower than Brazil (62.1%)^[@ref12],[@ref52]^ and Argentina (61.1%) ^[@ref39]^ in Latin America and some European countries (84.5%). ^[@ref9],[@ref53]-[@ref56]^

Our study had some limitations, including lack of published data from certain regions of Iran and the unavailability of some in-press articles that were excluded from our study.

Conclusion {#sec1-5}
==========

In conclusion, this study showed that the prevalence of CTX-M-type ESBLs-producing *K. pneumoniae* is diverse in different regions of Iran, and the central and eastern regions have higher RF compared to western regions.
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